ONCODESIGN PM overview

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2024 financial results, approved by the Board of Directors on April 3, 2025. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: "2024 was a very busy year for all our R&D programs, particularly OPM 101 and 201 in the clinic. OPM 101 is positioned in...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a clinical-stage company developing innovative therapies to overcome immune evasion and drug resistance, today announced the submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial REVERT ( R IPK2 for r E sistant and ad V anced m E lanoma t R eatmen T ) with OPM-101, its RIPK2 inhibitor in advanced melanoma patients with resistance to anti-PD-1. This submission of the study...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the appointment of Christophe Thurieau, Executive Director Research at Servier, as a member of the Board of Directors. Christophe Thurieau, a healthcare executive with more than 35 years of experience in the field, is joining the OPM team as an independent member of the...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories. The Phase I healthy volunteer study, initiated in October 2022, has just been completed, confirming the safety of OPM-201 in healthy volunteers. Final...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced the results of its annual General Meeting, which took place at 2:30pm on 30 May 2023, and the nomination of Florence Dupré as a member of its Board of Directors. Karine Lignel, Deputy CEO and COO, said : "I am very pleased with the way that OPM's first annual General...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2022 financial results. Philippe GENNE, Chief Executive Officer of Oncodesign, said: "OPM officially started its activity in September 2022 following the split with Oncodesign Biotechnology SA, and was listed on Euronext Growth in December by successfully raising €8 million...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a clinical stage biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the clinical entry of its drug candidate ODS-101 with the first subject dosing in Phase 1 clinical trial in healthy volunteers. Philippe Genne, Chairman and CEO of OPM, commented : " This is a very important milestone for Oncodesign Precision...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today publishes its indicative financial calendar for 2023. Event Date* 2022 Annual Results April 4, 2023 Annual General Meeting May 30, 2023 2023 First Half Results September 19, 2023 *subject to modification. Publication after financial market close. About Oncodesign...